Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin(R)-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10 /PRNewswire/ --     Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel
class of targeted human protein therapeutics, today announced significant
progress in validating novel, effective products for the potential treatment
of asthma. In studies of its proprietary PRS-060 Anticalin(R) candidate, the
Company reports that the protein can be effectively delivered to its target
of action via the lungs.

PRS-060 has been selected by Pieris as being specific for a target
implicated in a mechanism underlying asthma and other atopic diseases. The
mode of action of the Anticalin(R) candidate is via modulation of the site of
binding for multiple ligands.

"This important milestone demonstrates the exciting potential of
Anticalin(R)-based products for the treatment of respiratory disease," said
Dr Andreas Hohlbaum, Director of Science and Preclinical Development of
Pieris. "In a simple preclinical biodistribution study quantitating PRS-060
Anticalin(R) delivered via a microspray device, we have already observed
about 10-fold higher PRS-060 uptake than that typically obtained with
monoclonal antibodies. Our findings have demonstrated the potential to
deliver Anticalins(R) through alternative routes to injection and thereby
exploit their intrinsic robustness and stability."

"This study confirms the ability of PRS-060 to be formulated in a way
ideally suited to its application in asthma, namely in an inhaled preparation
for home use," noted Evert Kueppers, Pieris Chief Executive Officer. "These
findings continue to support the view that our Anticalin(R) platform,
including its recent validation for dual targeting purposes, has enormous
potential for application to human diseases that are currently inadequately
treated."

The data will be presented for the first time on August 9th 2007 at IBC's
Drug Discovery Technology Conference in Boston, MA, USA.

Pieris is now actively seeking development partners for this program with
specialization in product development for respiratory diseases, including
asthma.

Anticalin(R) and Duocalin(R) are registered trademarks of Pieris AG.

Further information is available at http://www.pieris-ag.com

For further information, please contact:

    Pieris AG
    Dr Birgit Zech, Senior Manager Business Development
    Phone +49-(0)-8161-1411-400